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ORIGINAL ARTICLE
Low dose histone deacetylase inhibitor, depsipeptide (FR901228),
promotes adenoviral transduction in human rhabdomyosarcoma
cell lines
FARIBA NAVID, BLAINE T. MISCHEN & LEE J. HELMAN
Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-1928, USA
Abstract
Purpose. Transduction of rhabdomyosarcoma (RMS) cells with adenoviral vectors for in vivo and in vitro applications has
been limited by the low to absent levels of coxackie and adenovirus receptor (CAR). This study investigates the potential use
of low doses of a histone deacetylase inhibitor, depsipeptide (FR901228), currently in Phase II human trials, to enhance
adenoviral uptake in six rhabdomyosarcoma cell lines.
Methods. Differences in adenoviral uptake in the presence and absence of depsipeptide (FR901228) were assessed using an
adenoviral construct tagged with green fluorescent protein. Changes in CAR and av integrin expression RMS in response to
pretreatment with depsipeptide (FR901128) was determined using RT-PCR.
Results. Pretreatment of five of six RMS cell lines with 0.5ng/ml of depsipeptide (FR901228) for 72h resulted in increased
viral uptake as assessed by green fluorescent protein expression. RT-PCR analysis for CAR showed that in four of these five
cell lines, CAR expression was increased 2.8–8.1-fold in cells treated with depsipeptide (FR901228) as compared to control.
av integrin expression was substantially increased in the one cell line, RH5, which showed increased GFP expression in
response to depsipeptide (FR901228) pretreatment but a minimal increase in CAR expression.
Conclusions. Depsipeptide (FR901228) can be used as a vehicle to enhance adenoviral transduction in a majority of RMS
cells. The mechanism of increased viral uptake appears to mediate via upregulation of CAR.
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Introduction
Rhabdomyosarcoma (RMS) is the most common
soft tissue sarcoma in childhood. Novel treatments
are required to improve the poor survival rates of
patients that present with advanced disease. Gene
therapy, using adenoviral constructs, is one potential
therapeutic strategy. Adenoviral infections are
advantageous because of their ability to infect both
dividing and nondividing cells, their large packaging
capacity and their ability to propagate high-titer viral
stocks. However, the relatively low efficiency of
recombinant gene transfer to tumor cells, including
RMS cells, has been a disadvantage to the use of
adenovirus in gene therapy.
Adenoviralinfectionofacellrequiresthebindingof
the knob domain of the fiber capsid protein of the
virus to the primary cellular receptor, coxackie and
adenovirus receptor (CAR).
1 The attachment the
virus to CAR may be facilitated by heparin sulfate
proteoglycans or sialic acid.
2,3 Subsequent internali-
zation of the virion by receptor-mediated endocytosis
is potentiated by the interaction of RGD peptide
sequences in the penton base of the virus with
secondary host cell receptors, integrins avb3 and
avb5.
4 In addition, adenoviral entry requires the
activation of the phosphatidylinositol-3-OH kinase
and the Rho family GTPase signaling pathways which
target the actin cytoskeleton.
5 How actin facilitates
internalization of the virus is unknown.
A number of studies have reported that cancer cells
express only low levels of CAR and are therefore
poorly infected by adenovirus.
6–8 Using flow cyto-
metry and immunohistochemistry, Cripe et al. have
shown that RMS cell lines and primary tumor
samples, respectively, have low to absent levels of
CAR but adequate av integrin levels. Also, increasing
CAR levels through transfection of CAR cDNA into
RMS cells rendered them highly susceptible to
adenovirus infection.
9 In a number of cell types,
methods to achieve CAR-independent gene transfer
have been utilized. These include modifications in
adenoviral vectors as well as the use of polycations to
altertheelectrostaticrepulsionbetweenthenegatively
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An alternative strategy would be to increase the level
of CAR in tumor cells.
Depsipeptide (FR901228), is a histone deacetylase
inhibitor isolated from Chromobacterium violaceum
No. 968.
14,15 By increasing the acetylation of histones
and thereby activating transcription, histone deacety-
lase inhibitors (HDIs) modulate the expression of
genes involved in a number of cellular processes
including inhibition of cell growth, promotion of
differentiation and reversion of a transformed pheno-
type.
16,17 Previous reports have shown that inhibitors
of histone deacetylase, trichostatin A and butyrate,
can increase adenoviral transgene expression at the
transcriptional level.
18–20 Recently, Kitazono et al.
demonstrated an increase in CAR, av integrin and
adenovirus-mediated gene expression in several
carcinoma cell lines and hematopoetic cells pre-
treated with depsipeptide (FR901228).
8,21 In the
present study, we describe the use of low dose
depsipeptide to enhance adenoviral transduction in
a panel of six rhabdomyosarcoma cell lines.
Materials and Method
Cell culture and reagents
Rh30, Rh5, Rh13 and Rh18 are cell lines cultured
from human alveolar rhabdomyosarcoma tumors.
22
RD4a is a subclone of a well established human
embryonal rhabdomyosarcoma cell line, RD.
23 CTR
(obtained from Dr. Maria Tsokos, National Cancer
Institute, Bethesda, MD) is a human embryonal
rhabdomyosarcoma cell line.
24 All cell lines were
cultured in RPMI 1640 with 10% fetal bovine serum
(FBS), 100U/ml of penicillin, 100mg/ml streptomy-
cin and 2mM L-glutamine at 37 C and 5–6% CO2.
Depsipeptide, FR901228, was obtained from
the Pharmaceutical Management Branch, Cancer
Therapy Evaluation Program, National Cancer
Institute (Bethesda, MD).
MTT assay
Cells were plated in triplicate in 96-well plates at
a density of 5 10
3/well. Twenty-four hours later,
media was removed and replaced with media
containing various concentrations of depsipeptide
(FR901228). Control cells were treated with iden-
tical concentrations of DMSO (diluent for depsipep-
tide). After 72h, cell number was determined using
colorimetric MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) (Sigma Chemical Co.,
St. Louis, MO) assay as previously described.
25,26
Absorbencies were measured on a Titertek enzyme-
linked immunosorbent assay reader using a test
wavelength of 570nm and a reference wavelength of
690nm. The optical density measurements were
converted to cell number using a standard curve.
Adenoviral infection
RMS cells were plated at a density of 2.5 10
5 cells
in six-well plates. After 24h, 0.5ng/ml of depsipep-
tide (FR901228) was added to designated wells and
DMSO to the control wells. Seventy-two hours later
the cells were incubated for 1h with equal amounts
of adenovirus, AdU1, in serum free media. AdU1 is
an E1 and E3 deleted replication defective type 5
adenovirus with a GFP cassette driven by a CMV
promoter.
27 AdU1 titre of 1 10
11 TCID50/ml was
determined by the TCID50 assay as described by
Qbiogene (Carlsbad, CA) except that the presence of
GFP-positive cells instead of cytopathy was used as
an indicator of viral infection.
Western blot analysis
Cells were washed twice with 1 PBS and then lysed
with Lamelli buffer (0.125M Tris, 20% glycerol, 4%
SDS, pH 6.8) and protease inhibitors (Complete
Mini, EDTA free, protease inhibitor cocktail tablets
(Roche Diagnostic Corporation, Indianapolis,
IN). Protein concentration was determined using
Bio-Rad DC Protein Assay (Bio-Rad Laboratories,
Hercules, CA). Ten mg of protein were resolved on a
NOVEX 4–20% Tris–glycine gel (Invitrogen
Corporation, Carlsbad, CA) and transferred onto a
nitrocellulose membrane overnight at 20V using a
wet electroblotting system. Membranes were probed
with rabbit anti-human GFP antibody protein
(1:5000) (Invitrogen) and mouse monoclonal anti-
human a-tubulin (0.1mg/ml) (Ab-1) (Oncogene
Research Products, Cambridge, MA). Nuclear
protein was isolated to assess levels of histone H3
and acetylated histone H3. RMS cells treated for 72h
with depsipeptide or DMSO were washed twice with
1 PBS. The cells were lysed in 10mM Hepes (pH
7.9), 1.5mM MgCl2, 10mM KCl, 0.5mM DTT
and protease inhibitors and spun at 12000rpm for
15min at 4 C. Supernatant was removed and 50ml
of 50mM Hepes, 420mM KCl, 0.1mM EDTA (pH
8), 5mM MgCl2, 0.5mM DTT, and 20% glycerol
were added and subjected to three cycles of freezing/
thawing. The mixture was spun at 12000rpm for
15min at 4 C. Equal volumes of supernatant and
Lamelli buffer were loaded onto a 4–20% Tris–
glycine gel and transferred as described above. Blots
were probed with rabbit polyclonal anti-histone H3
(2mg/ml) (catalog 06-755) (Upstate Biotechnology,
Lake Placid, NY) and rabbit polyclonal anti-acetyl
histone H3 (1mg/ml) (catalog 06-911) (Upstate
Biotechnology).
RT-PCR
RT-PCR was performed using Ready-To-Go RT-
PCR beads (Amersham Pharmacia Biotech, Inc.,
Piscataway, NJ). Each reaction was performed using
26 F. Navid et al.1mgRNA, 0.5mg of pd(T)12–18 and 0.2mM of the
following gene specific primers and PCR conditions.
Human CAR primers: sense 50-GATCAGTGCC
TGTTGCGTCTA and antisense 50-TCACAGG
AATCGCACCCA (product size¼399 bp); 42 C
30min, 95 C 5min, 30 cycles 95 C3 0s ,5 5  C3 0s ,
72 C 1min, 1 cycle 72 C 10min. Human av integrin
primers:
8 sense 50-TAAAGGCACATGGCAAAGG
AGT and antisense 50-CAGTGGAAATGGAAA
CGATGAGC (product size¼490 bp): 42 C
30min, 95 C 5min, 28 cycles 94 C2 0 s ,6 4  C
40s, 72 C 1min, 1 cycle 72 C 10min. Human
GAPDH primers: sense 50-AAGGTCGGAGTCAA
CGGATT and antisense 50-CATTGATGACAAGC
TTCCCG. The PCR products were cloned and
sequenced to verify that the amplified product was
the gene of interest.
Results and Discussion
We first determined the effect of various concentra-
tions of depsipeptide (FR901228) on six RMS cell
lines since depsipeptide (FR901228) has been shown
to have antitumor activity as well as alter the growth
of tumor cells. The growth inhibition of RMS cells
treated with  0.5ng/ml depsipeptide (FR901228)
for 72h was less than 20% compared to controls
(Fig. 1a). Since our purpose was to use depsipeptide
to modulate the efficiency of viral infection in these
tumor cells and not to use the drug for its antitumor
activity, we conducted the subsequent experiments
with 0.5ng/ml of depsipeptide (FR901228). As
shown in Fig. 1b for the CTR cell line, an increase
in acetylated histone H3 occurs at this low dose of
depsipeptide (FR901228).
In order to study the ability of depsipeptide
(FR901228) to enhance adenovirus-mediated gene
transfer in RMS cells, we infected six RMS cell lines
with an adenoviral vector containing a CMV
promoter driven green fluorescent protein (GFP)
gene. Cells infected with this virus can be visualized
under a fluorescent microscope and GFP can
be quantitated by Western analysis. As shown in
Fig. 2a, five of the six cell lines pretreated with
depsipeptide (FR901228) had increased GFP
expression compared to the untreated control cells.
The degree of GFP protein expression, quantitated
by Western blot analysis, was 8.6–2.6-fold greater in
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Fig. 1. Effect of depsipeptide (FR901228) on the growth of RMS cell lines and acetylation of histone H3. (a) Six RMS cell lines
(RD4a, CTR, RH5, RH13, RH18, and RH30) were plated in triplicate in a 96-well plate at a density of 5 10
3cells/well. Twenty-
four hours later, the cells were incubated with different concentrations of depsipeptide (FR901228) or DMSO (diluent for depsipeptide).
Cells were harvested after 72h of treatment. Cell number was determined using a colorimetric MTT assay. The bars indicated represent
standard deviation from the mean of triplicate samples. (b) Western blot analysis for histone H3 acetylation in CTR cells in response to
72h treatment with depsipeptide (þ) or DMSO ( ). Histone H3 serves as a control for loading of nuclear protein lysates.
FR901228 modulates adenovirus uptake in rhabdomyosarcoma 27the depsipeptide-treated cells then in the untreated
control cells (Fig. 2b). No GFP protein expression
was detected in the CTR cell line.
Adenoviral infection is mainly dependent on
the presence of CAR on the surface of normal as
well as malignant cells. Because CAR expression
has been reported to be low or sometimes absent in
RMS cell lines and tissues, we investigated whether
the increased adenoviral expression observed in the
RMS cell lines treated with depsipeptide
(FR901228) was due to increased CAR expression
in these cell lines. Using RT-PCR, we were able
to detect transcripts for CAR in five of six cell
lines. In addition, four of six RMS cells treated
with depsipeptide for 72h showed a 2.8–8.1-fold
increase in CAR expression compared to untreated
cells (Fig. 3a). RH30 had the greatest increase
in CAR expression in response to depsipeptide
GFP
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Fig. 2. Adenoviral GFP expression in RMS cell lines pretreated with depsipeptide (FR901228). RMS cells were plated at a density of
2.5 10
5 cells in six-well plates. After 24h, 0.5ng/ml of depsipeptide (FR901228) was added to designated wells and DMSO to the
control wells. Seventy-two hours later the cells were incubated for 1h with equal amounts of adenovirus, AdU1, in serum free media.
The cells were replenished with complete media. For each cell line pretreated with depsipeptide (FR901228) (þ) or DMSO ( ),
fluorescent (top) and phase contrast (bottom) photographs were taken 72h after adenoviral infection (a). Media was then removed
and the cells were harvested for protein. Levels of green fluorescent protein expression were assessed using Western blot analysis.
Densitometry was performed using NIH Image 1.60 software and was used to calculate the fold change in protein expression. a-Tubulin
was used to normalize the protein loading.
28 F. Navid et al.(FR901228), and showed the greatest increase in
adenoviral uptake in response to depsipeptide
(FR901228) pretreatment. Unlike Rh30, RH5 had
minimally upregulated CAR expression in the pre-
sence of depsipeptide (FR901228); however, a 2.8-
fold increase in adenoviral uptake in response to
pretreatment with depsipeptide was observed. In
contrast, av integrin expression was present in all six
cell lines, and was modulated by depsipeptide
(FR901228) 1.5–6.9-fold in four of the six RMS
cell lines, including RH5 (Fig. 3b). The increased
adenoviral uptake in RH5 cells in response to
depsipeptide (FR901228) may be due to a 6.6-fold
increase in av integrin. Even though we detected a 2-
fold increase av integrin expression in the CTR cell
line, we observed no viral uptake in this cell line.
This is probably due to the lack of CAR expression
in both the presence and absence of depsipeptide
(FR901228), suggesting that the presence of CAR is
critical for adenoviral gene transfer.
We conclude that depsipeptide (FR901228)
modulates adenovirus transgene expression through
upregulation of the viral receptor, CAR and in some
cases av integrin, in RMS cells. The change in gene
expression is variable between the different RMS
cell lines. These findings are similar to what has
been reported for carcinoma cell lines and hemato-
poetic cells.
8,21 The mechanism of increased gene
expression is presumed to be release of transcrip-
tion repression through inhibition of histone deace-
tylases. As an efficient means of exogenous gene
expression, the addition of low dose depsipeptide
(FR901228) to promote adenoviral uptake may
be a simple and useful approach for in vitro studies
of rhabdomyosarcoma cells. Since depsipeptide
(FR901228) is currently in adult Phase II trials and
in a pediatric Phase I trial, the use of this agent in vivo
is plausible and could be used for the purpose of
increasing the efficacy of adenoviral mediated gene
therapy.
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